The Comirnaty 2025-2026 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, a descendant of JN.1. The Food and Drug Administration (FDA) has approved Comirnaty ® (LP.8.1-adapted monovalent ...
COVID-19 vaccine recommendations could be changing, according to the U.S. Food and Drug Administration. FDA leaders said on May 20 that clinical trials will be required to approve annual COVID-19 ...
The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1 Shipping of the LP.8.1-adapted vaccine will ...
Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to ...
The FDA approved 2025-2026 COVID vaccines from Pfizer (Comirnaty), Moderna (Spikevax, mNexspike), and Novavax (Nuvaxovid), the companies announced on Wednesday. But the agency removed one of the ...
Mayo Clinic on MSN
Different types of COVID-19 vaccines: How they work
Find out how different vaccines for the coronavirus cause your body to create antibodies that fight the virus.
LONDON (Reuters) -Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal. Last ...
Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: Coronavirus disease (COVID-19) vaccination campaign in Ronda LONDON (Reuters) -Pfizer and its German partner BioNTech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results